FindTrial
Sign In

Effects of Dexmedetomidine on Percutaneous Nephrolithotomy during spinal anesthesia

Effects of Dexmedetomidine on Percutaneous Nephrolithotomy during spinal anesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003843
Enrollment
Unknown
Registered
2013-11-18
Start date
2013-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal stones

Interventions

Group C:NS
Group D1:0.5µg/kg Dexmedetomidine
Group D2:0.75µg/kg Dexmedetomidine
Group D3:1.0µg/kg Dexmedetomidine
Group M:1.0µg/kg Dexmedetomidine

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The patients undergoing selective operation of Percutaneous Nephrolithotomy; Aged 18 to 65 years; BMI 18 to 25.

Exclusion criteria

Exclusion criteria: The patients have got serious diseases of the cardiovascular system, bradycardia, atrioventricular block, Liver and kidney dysfunction or Dexmedetomidine anaphylaxis; The patients have got myasthenia gravis, acute alcoholism, organic brain damage or severe respiratory insufficiency.

Design outcomes

Primary

MeasureTime frame
blood pressure;heart rate;oxyhemoglobin saturation;body temperature;OAA/S;VAS;nausea and vomiting;Chills ratin;—

Countries

China

Contacts

Public ContactLina Lin

The First Affiliated Hospital of Wenzhou Medical University

wzlinlina@163.com+86 13587688101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026